Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | METAP1 | P53582 | 3/20 | 0.55 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4358495 | 0.91 | ACHE (0.61) | ACHEMETAP1MAP2K3CYP19A1ALDH1A1 | |
| SCHEMBL7573550 | 0.88 | METAP1 (0.56) | ACHEMETAP1MAP2K3CYP19A1ALOX15 | |
| SCHEMBL9148955 | 0.84 | CYP19A1 (0.59) | ACHEMAP2K3CYP19A1ALOX15ALOX12 | |
| SCHEMBL29218130 | 0.81 | MAP2K3 (0.47) | ACHEMAP2K3CYP19A1ALOX15ALOX12 | |
| SCHEMBL1346365 | 0.81 | ACHE (0.64) | ACHEMETAP1MAP2K3CYP19A1CYP3A4 | |
| SCHEMBL9146594 | 0.79 | CYP19A1 (0.63) | METAP1CYP19A1ALDH1A1MAOBHTR2A | |
| SCHEMBL3860892 | 0.79 | ACHE (1.00) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL29894949 | 0.79 | ACHE (1.00) | ACHEMETAP1CYP19A1HTR2AHTR2C | |
| SCHEMBL4429729 | 0.78 | MAP2K3 (0.56) | ACHEMAP2K3CYP19A1ALOX15ALOX12 | |
| SCHEMBL16311356 | 0.78 | ACHE (0.69) | ACHEMETAP1CYP19A1ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| EP-2074102-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | ESR1, GPER1, ESR2 | ACHE 2099/4885METAP1 4254/4885MAP2K3 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.